Detragel, gel 40 g

Combination drug, has local anticoagulant, anti-inflammatory, venotonic and anti-aggregant effect, reduces venous permeability, improves microcirculation.

Detragel® contains three active ingredients: sodium heparin, essential phospholipids and escin, which have pharmacodynamic and pharmacokinetic synergism.

Sodium heparin is a direct acting anticoagulant. Due to inactivation of biogenic amines and blocking of lysosomal enzymes in the tissue it shows anti-inflammatory effect, accelerates dissolution of micro clots in the subcutaneous capillaries, prevents thrombosis, activates the fibrinolytic system, improves microcirculation, promotes regeneration of connective tissue due to inhibition of hyaluronidase activity.

Essential phospholipids decrease blood viscosity through their influence on fat metabolism and decrease the process of platelet aggregation.

Escin is a venotonic agent of plant origin. It prevents the activation of lysosomal enzymes that break down proteoglycan, increases the tone of the venous wall, eliminates venous stasis, decreases capillary permeability and fragility. It reduces exudation, decreases effusion of fluid into tissues and accelerates resorption of existing edema. Inhibits inflammatory processes, improves microcirculation, promotes tissue repair.

Indications

Active ingredient

Composition

Active ingredients in 1 g of the product:

Directions for use

For external use.

The gel is applied in a thin layer to the problem area of the skin and distributed evenly by gentle massaging movements, 2-3 times a day until symptoms disappear.

If necessary, the gel can be applied under elastic stockings or bandages.

To avoid rubbing the gel in thrombophlebitis.

Application of the gel on mucous membranes is contraindicated.

The duration of treatment is not more than 15 days. The possibility of a longer course of treatment is determined by the doctor.

If the condition worsens or does not improve after 15 days, the patient should see a doctor.

The recommended dose and duration of treatment should not be exceeded.

Special Instructions

To date, there have been no reports of adverse effects on the mother and fetus when using the drug in pregnant women.

The use during pregnancy and during breastfeeding is possible only when the expected benefit of the therapy for the mother exceeds the potential risk for the fetus, so a physician should be consulted before using the drug.

Medications for topical use, especially after long-term use, have sensitizing effects. If this occurs, treatment with the medication should be stopped, and appropriate treatment prescribed if necessary.

Protrombin time and clotting time should be monitored during prolonged use of the drug on large areas of skin and concomitant use of indirect anticoagulants (warfarin, acenocoumarol and others).

Detragel® is not recommended for use in deep vein thrombosis.

If the patient’s condition worsens or does not improve after 15 days, the patient should see a physician.

Contraindications